The global market for rizatriptan benzoate is expected to grow at a significant CAGR during the forecast period (2021-2027). Rizatriptan is a migraine medication. It relieves headaches, discomfort, and other migraine symptoms (such as nausea, vomiting, and light/sound sensitivity). The global market for rizatriptan benzoate is expected to grow at a significant CAGR during the forecast period (2021-2027). Rizatriptan is a migraine medication. It relieves headaches, discomfort, and other migraine symptoms (such as nausea, vomiting, and light/sound sensitivity). Treatment allows you to go back to your usual routine and may reduce your need for further pain medications. Rizatriptan is a triptan, which is a kind of medication. It affects a natural chemical called serotonin, which causes blood vessels in the brain to constrict. It may also help to alleviate pain by influencing specific brain nerves. Rizatriptan does not reduce the frequency of migraine attacks or prevent future headaches.

Migraine is a neurovascular illness that affects more than one billion individuals across the globe. Its extensive incidence and accompanying impairment have a wide variety of unpleasant and significant consequences for people who are directly afflicted, as well as their families, coworkers, employers, and society. To alleviate this worldwide burden, concerted efforts are required to adopt and enhance migraine treatment, which is backed up by sound healthcare policy.

According to the National Library of Medicines survey 2018, in the adult population of the United States, the prevalence and burden of self-reported migraine and severe headache is significant, impacting about one out of every six Americans and one out of every five women over three months (15.3 % overall) 9.7 %  of males and 20.7 % of females. Over 19 years, the prevalence has remained relatively constant. Thus the rising prevalence of migraines globally is expected to drive the growth of the global rizatriptan benzoate market. In September 2021, IntelGenx Corp. reported that it had collaborated with Exeltis Healthcare S.L. for the marketing of Rizaport, a novel therapy for acute migraines, in the European Union (“EU”) and that the medication had been launched in Spain. Rizaport is a brand name for rizatriptan benzoate, a 5-HT1 receptor agonist and the active ingredient in Merck & Co.'s Maxalt.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product Type 

o By Distribution Channel

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Merck & Co., Pharmathen, Pfizer Inc., Novartis AG, Glenmark Pharmaceuticals, Natco Pharma.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rizatriptan Benzoate Market by Segments 

By Product Type

• Tablets
• Capsules

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Rizatriptan Benzoate Market by Region